

Preventing colorectal cancer through early detection



Early detection leads to healthier employees

A devastating, yet preventable disease

Colorectal cancer is the second leading cause of cancer deaths in the United States and, according to the American Cancer Society, more than 50,000 people will die from it in the U.S. in 2018.¹ Providing early detection of colorectal cancer can improve survival rates, yet 1 in 3 adults aged 45 to 75 have not been tested for colorectal cancer as recommended by the American Cancer Society.²

“There are more than 20 million adults in this country who haven’t had any recommended screening for colorectal cancer and who may therefore get cancer and die from a preventable tragedy. Screening for colorectal cancer is effective and can save your life.”

-CDC Director Tom Frieden, MD, MPH

Screening that makes a difference

InSure® ONE™, a fecal immunochemical test, is proven to detect lower GI tract bleeding, which may be caused by colorectal cancer or other causes. Its cost-effectiveness is clear when used as an initial screening option in lieu of more invasive procedures. InSure ONE can provide early detection when it comes to the screening for, and prevention of, colorectal cancer within your population.

How it works



InSure ONE kit mailed to individual



Individual collects sample at home and mails completed kit back to Quest Diagnostics



Quest Diagnostics performs and interprets tests



Results sent to individual



Negative (non-detected)

Individual advised to share results with personal physician.



Positive (detected)

Individual advised to share results with personal physician because further clinical evaluation is recommended.

The self-administered collection is a convenient, in-home colorectal cancer screening with no food or prescription restrictions, and is ideal for filling the gaps in care in your population. Results are mailed to the individual.



“I had surgery last year. They took out a part of my colon that had a tumor. It was discovered as the result of an at-home cancer screening. I am so grateful to be alive and well today. I can look forward to retirement and time with my grandchildren. It saved my life before I even knew I was in danger.”

—Participant screened by Quest Diagnostics

Achieve higher compliance with these key differentiators

- Water-based collection method
- Non-invasive methodology, no fecal handing, poking, or smearing required
- Two samples from a single bowel movement
- Specimen is stable for 14 days following collection

Quest Diagnostics manages the entire process from beginning to end:

1 Program planning

- Contracting
- Account management
- Eligibility processing
- Program communications

2 Program implementation

- Kit mailing
- Reminder program
- Physician oversight
- Lab-based testing
- Monthly summary report

3 Post program

- Participant reporting
- Health plan reporting
- Third-party data feed (if applicable)

The odds that an employee will develop colorectal cancer are high—averaging about 5 percent for both men and women in the U.S. according to the American Cancer Society.³

Contact a Quest Diagnostics Health & Wellness representative today about offering a non-invasive colorectal cancer screening program to close gaps in care in your population.

1. American Cancer Society, Cancer Facts & Figures 2018. Atlanta, Ga: American Cancer Society; 2018.

2. American Cancer Society, Guideline for Colorectal Cancer Screening. Atlanta, Ga: American Cancer Society; 2018.

3. CA – A Cancer Journal for Clinicians: Colorectal cancer statistics, 2014.

InSure®/InSure® ONE™ are trademarks of Enterix Inc. and Enterix Pty. Ltd.

Enterix Inc., A Clinical Genomics Inc. Company

Quest Diagnostics, the associated logo, and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics.

All third-party marks—® and ™—are the property of their respective owners. © 2018 Quest Diagnostics Incorporated. All rights reserved. 6/18